

GUJARAT TECHNOLOGICAL UNIVERSITY
Pharm D – 3rd Year • EXAMINATION – SUMMER-2023

Subject Code: 838801**Date: 07\07\2023****Subject Name: Pharmacology-II****Time: 02:30 PM TO 05:30 PM****Total Marks: 70****Instructions:**

1. Attempt any five questions.
2. Make suitable assumptions wherever necessary.
3. Figures to the right indicate full marks.

- Q.1** (a) Write a short note on Anti-cancer antibiotics. **06**
(b) Differentiate: Cyclophosphamide v/s Methotrexate **04**
(c) Describe in detail retroviral based gene therapy with examples and schematic diagram. **04**
- Q.2** (a) Classify Anti-retroviral agents based on mechanism of action and differentiate Saquinavir vs. Enfuvirtide **06**
(b) Describe important characteristics of cancer cells. **04**
(c) Differentiate: Zidovudine vs. Raltegravir **04**
- Q.3** (a) Give detail classification of immunosuppressant drugs and discuss compare/contrast between Mycophenolate Mofetil and Tacrolimus. **06**
(b) Differentiate: Vincristine vs. Etoposide **04**
(c) Classify anti-malarial agents and discuss in detail on Artemisinin semisynthetic derivatives. **04**
- Q.4** (a) Write a short note on second generation anti-TB drugs with each drug discuss in detail. **06**
(b) Differentiate: Amphotericin-B vs. Griseofulvin **04**
(c) Describe in detail Jak/Stat cell signaling pathway. **04**
- Q.5** (a) Write a short note on broad spectrum antibiotics, specially emphasizing on tetracyclines and Chloramphenicol. **06**
(b) Differentiate: Rifampicin vs. Isoniazid **04**
(c) Differentiate: Oseltamivir vs. Acyclovir **04**
- Q.6** (a) Classify penicillins and write a short note on anti-pseudomonal penicillins. **06**
(b) Discuss in detail cell cycle with restriction points and cell cycle regulators. **04**
(c) Discuss mechanism of action of co-trimoxazole and enlist its therapeutic uses and side effects. **04**
- Q.7** (a) Give detail classification of diuretics and discuss about high ceiling diuretics. **06**
(b) Differentiate: Vancomycin vs. Linezolid **04**
(c) Write a general protocol for sub-acute oral toxicity study according to OECD guideline **04**
